Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clove Oil→

Clove Oil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8000-34-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Botanical essential oileugenol-rich topical dental analgesic and antiseptic ingredient
Mechanism of action
Eugenol modulates transient receptor potential and voltage-gated ion channels and can inhibit local nociceptive signalling. It also has local antimicrobial effects; activity depends on oil composition and concentration.
Indications / reported uses
  • Temporary local relief of dental pain and use as a dental antiseptic or obtundent in selected dental preparations; should be used in appropriate dental formulations and not as a substitute for definitive dental treatment

Sources: NLM MeSH — Clove oil · PubMed — Eugenol dental analgesic pharmacology · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Botanical essential oil; eugenol-rich topical dental analgesic and antiseptic ingredient

Mechanism of action

Eugenol modulates transient receptor potential and voltage-gated ion channels and can inhibit local nociceptive signalling. It also has local antimicrobial effects; activity depends on oil composition and concentration.

General use cases

  • Temporary local relief of dental pain and use as a dental antiseptic or obtundent in selected dental preparations; should be used in appropriate dental formulations and not as a substitute for definitive dental treatment

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Clove Oil Environmental Risk Assessment (ERA) (the Clove Oil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.